What is HC Wainwright’s Forecast for ACRS FY2026 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Analysts at HC Wainwright increased their FY2026 earnings estimates for Aclaris Therapeutics in a research note issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of ($0.57) for the year, up from their prior forecast of ($0.61). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2026 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.51) EPS.

A number of other analysts have also recently issued reports on the company. Canaccord Genuity Group raised their price objective on Aclaris Therapeutics from $10.00 to $13.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Craig Hallum set a $9.00 target price on Aclaris Therapeutics in a report on Wednesday, October 28th. Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Finally, Wedbush cut their price target on Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Wednesday, October 28th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $11.33.

Get Our Latest Report on Aclaris Therapeutics

Aclaris Therapeutics Trading Down 7.8%

Aclaris Therapeutics stock opened at $4.00 on Wednesday. Aclaris Therapeutics has a 52 week low of $2.25 and a 52 week high of $6.60. The stock has a 50-day simple moving average of $4.47 and a 200 day simple moving average of $4.53.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.04. Aclaris Therapeutics had a negative net margin of 1,244.09% and a negative return on equity of 59.19%. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.27 million.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently bought and sold shares of ACRS. HighTower Advisors LLC grew its position in shares of Aclaris Therapeutics by 3.5% in the third quarter. HighTower Advisors LLC now owns 225,190 shares of the biotechnology company’s stock valued at $1,184,000 after purchasing an additional 7,666 shares during the last quarter. Alps Advisors Inc. lifted its holdings in Aclaris Therapeutics by 37.6% during the 3rd quarter. Alps Advisors Inc. now owns 195,036 shares of the biotechnology company’s stock worth $1,026,000 after purchasing an additional 53,287 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Aclaris Therapeutics during the 3rd quarter worth approximately $40,000. Profund Advisors LLC lifted its holdings in Aclaris Therapeutics by 462.3% during the 3rd quarter. Profund Advisors LLC now owns 171,421 shares of the biotechnology company’s stock worth $902,000 after purchasing an additional 140,935 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Aclaris Therapeutics by 20.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 26,858 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 4,630 shares during the period. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

(Get Free Report)

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.

Recommended Stories

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.